Clinical effect of decitabine combined with low-dose chemotherapy in the treatment of elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia
Objective To study the clinical effect of decitabine and low dose chemotherapy combination in elderly pa-tients with high risk myelodysplastic syndrome and acute myeloid leukemia.Methods Ninety-two elderly patients with high-risk myelodysplastic syndrome and acute myeloid leukemia admitted to the First Affiliated Hospital of Zheng-zhou University from April 2022 to April 2023 were selected.According to different treatment plans,46 patients receiv-ing low-dose chemotherapy were selected as the conventional group,and 46 patients receiving decitabine and low-dose chemotherapy combination were selected as the study group.The efficacy,clinical indexes and adverse reactions of the two groups were observed and compared.Results In terms of efficacy,the total effective rate of the study group(93.48％)was significantly higher than that of the conventional group(76.09％),and the difference between groups was statistically significant(P＜0.05).Before treatment,there was no statistical significance in the levels of vascular endothelial growth factor(VEGF),growth differentiation factor 11(GDF11)and soluble transfertransferin receptor(sTfR)between the two groups(P＞0.05).After treatment,the levels of VEGF,GDF11 and sTfR were decreased be-tween the two groups,and significantly decreased in the study group compared with the conventional group.The differ-ence was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the conventional group(15.22％)and the study group(4.35％)(P＞0.05).Conclusions The combina-tion of decitabine and low-dose chemotherapy in elderly patients with middle and high-risk MDS and AML can show a definite effect.
NETL
NSTL
万方数据
